Can we afford the costs of new developments in intensive care medicine?

被引：1

作者：

Boldt, J ^{[1
]}

机构：

[1] Klinikum Stadt Ludwigshafen, Klin Anasthesiol & Operat Intensmed, D-67063 Ludwigshafen, Germany

来源：

ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE | 2004年 / 39卷 / 04期

关键词：

D O I：

10.1055/s-2004-814388

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

[No abstract available]

引用

页码：191 / 196

页数：6

共 26 条

[1] Assessing the effectiveness of critical pathways on reducing resource utilization in the surgical intensive care unit [J].

Berenholtz, S ;

Pronovost, P ;

Lipsett, P ;

Dawson, P ;

Dorman, T .

INTENSIVE CARE MEDICINE, 2001, 27 (06) :1029-1036

[2] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[3]

FDA, 2001, FDA CLIN REV DROTR A

[4] Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial [J].

Follath, F ;

Cleland, JGF ;

Just, H ;

Papp, JGY ;

Scholz, H ;

Peuhkurinen, K ;

Harjola, VP ;

Mitrovic, V ;

Abdalla, M ;

Sandell, EP ;

Lehtonen, L .

LANCET, 2002, 360 (9328) :196-202

[5]

Forst H, 2003, ANAESTHESIST, V52, P1, DOI 10.1007/s00101-002-0450-2

[6]

Hoffman M, 1998, BLOOD COAGUL FIBRIN, V9, pS61

[7] Levosimendan improves diastolic and systolic function in failing human myocardium [J].

Janssen, PML ;

Datz, N ;

Zeitz, O ;

Hasenfuss, G .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :191-199

[8] Recombinant activated factor VII (rFVIIa): Characterization, manufacturing, and clinical development [J].

Jurlander, B ;

Thim, L ;

Klausen, NK ;

Persson, E ;

Kjalke, M ;

Rexen, P ;

Jorgensen, TB ;

Ostergaard, PB ;

Erhardtsen, E ;

Bjorn, SE .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (04) :373-383

[9] Treatment of traumatic bleeding with recombinant factor VIIa [J].

Kenet, G ;

Walden, R ;

Eldad, A ;

Martinowitz, U .

LANCET, 1999, 354 (9193) :1879-1879

[10] Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels [J].

Kersten, JR ;

Montgomery, MW ;

Pagel, PS ;

Warltier, DC .

ANESTHESIA AND ANALGESIA, 2000, 90 (01) :5-11

← 1 2 3 →